JP2021145581A - Composition for preventing or improving fructose-induced disease - Google Patents
Composition for preventing or improving fructose-induced disease Download PDFInfo
- Publication number
- JP2021145581A JP2021145581A JP2020046608A JP2020046608A JP2021145581A JP 2021145581 A JP2021145581 A JP 2021145581A JP 2020046608 A JP2020046608 A JP 2020046608A JP 2020046608 A JP2020046608 A JP 2020046608A JP 2021145581 A JP2021145581 A JP 2021145581A
- Authority
- JP
- Japan
- Prior art keywords
- fructose
- kestose
- composition
- group
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
Description
本発明は、フルクトース誘導性疾患の予防又は改善用組成物、及びそれを用いた飲食品又は医薬品に関するものである。 The present invention relates to a composition for preventing or ameliorating fructose-induced diseases, and foods and drinks or pharmaceuticals using the same.
メタボリックシンドロームは、肥満（内臓脂肪蓄積型肥満）を中心として、高血糖、高血圧、脂質代謝異常（高トリグリセライド血症、低ＨＤＬコレステロール血症）といった、動脈硬化性疾患と２型糖尿病発症のリスク因子が集積した病態といわれている。このような状態が重なり合って発症すると、心筋梗塞、脳梗塞等を起こす危険性が非常に高くなる。メタボリックシンドロームの原因である内臓脂肪が蓄積すると、脂肪細胞が肥大や増殖をし、アディポサイトカインの分泌異常が起こることが指摘されている。これが、動脈硬化を促進し、糖尿病、高血圧、脂質異常症を発症もしくは悪化させる原因となっている。アディポサイトカインのうち、例えばアディポネクチンは、本来は、傷ついた血管壁を修復する働きをしていて動脈硬化を予防するほか、インスリンの働きを高める作用、血圧を低下させる作用などがあるが、内臓脂肪が増えると、アディポネクチンの分泌が減少し、動脈硬化を防ぐ働きが低下し、またインスリン抵抗性の状態を引きおこし、血糖を上昇させる。従って、内臓脂肪の蓄積を予防することはメタボリックシンドロームを予防や改善する上で非常に重要である。 Metabolic syndrome is a risk factor for developing arteriosclerosis and type 2 diabetes, such as obesity (visceral fat accumulation obesity), hyperglycemia, hypertension, and dyslipidemia (hypertriglyceridemia, low HDL cholesterolemia). It is said to be a pathological condition in which obesity is accumulated. When such a state overlaps and develops, the risk of causing myocardial infarction, cerebral infarction, or the like becomes extremely high. It has been pointed out that when visceral fat, which is the cause of metabolic syndrome, accumulates, adipocytes enlarge and proliferate, resulting in abnormal secretion of adipocytokines. This promotes arteriosclerosis and causes diabetes, hypertension, and dyslipidemia to develop or worsen. Among adipocytokines, for example, adiponectin originally has a function of repairing damaged blood vessel walls to prevent arteriosclerosis, and also has an effect of increasing insulin function and an effect of lowering blood sugar, but visceral fat. When the amount of adiponectin increases, the secretion of adiponectin decreases, the function of preventing arteriosclerosis decreases, and insulin resistance is caused, and blood sugar is increased. Therefore, prevention of visceral fat accumulation is very important for prevention and improvement of metabolic syndrome.
フルクトース（果糖）は、スクロースの構成単糖として多量に摂取されてきたが、近年、トウモロコシのデンプンに含まれるブドウ糖を酵素によって果糖に変えて異性化糖にし、甘味を強めた高果糖コーンシロップ（高果糖ブドウ糖液糖）が開発され、清涼飲料水や菓子などからより摂取されるようになった。このフルクトースは、グルコースと異なり食後の血糖値やインスリンレベルの急激な上昇を引き起こさないが、フルクトースを過剰摂取することが、内臓脂肪肥満やメタボリックシンドローム、インスリン抵抗性の原因となり、糖尿病や動脈硬化を発症することがわかってきた。さらに、近年増加している非アルコール性脂肪性肝疾患（ＮＡＦＬＤ）や非アルコール性脂肪肝炎（ＮＡＳＨ）と、フルクトース過剰摂取との関係性が指摘されている（非特許文献１）。よって、今後益々、フルクトースの摂取を原因としたインスリン抵抗性、脂肪肝や高脂血症等の疾患の予防又は改善が重要となってくる。 Fructose (fructose) has been ingested in large quantities as a constituent monosaccharide of sucrose, but in recent years, high fructose corn syrup (high fructose corn syrup) with enhanced sweetness by converting glucose contained in corn starch into high fructose corn syrup by an enzyme. High fructose corn syrup) has been developed and is now more ingested from soft drinks and confectionery. Unlike glucose, this fructose does not cause a rapid rise in postprandial blood glucose and insulin levels, but overdose of fructose causes visceral fat obesity, metabolic syndrome, and insulin resistance, leading to diabetes and arteriosclerosis. It has been found that it develops. Furthermore, it has been pointed out that there is a relationship between non-alcoholic steatohepatitis (NAFLD) and non-alcoholic steatohepatitis (NASH), which have been increasing in recent years, and fructose overdose (Non-Patent Document 1). Therefore, it will become more and more important to prevent or improve insulin resistance, fatty liver, hyperlipidemia and other diseases caused by fructose intake.
特許文献１には、大豆由来のリゾ脂質を用いた、フルクトース誘導性疾患の予防剤又は改善剤が開示されている。 Patent Document 1 discloses a preventive agent or an ameliorating agent for fructose-induced diseases using soybean-derived lysolipids.
本発明は、フルクトース誘導性疾患の予防又は改善用組成物、及びそれを含む飲食品又は医薬品を提供することを目的とする。 An object of the present invention is to provide a composition for preventing or ameliorating fructose-induced diseases, and foods and drinks or pharmaceuticals containing the same.
本発明者は、上記課題を解決すべく鋭意研究を重ねた結果、１−ケストースがフルクトース誘導性疾患、特に内臓脂肪の蓄積を予防することを見出し、本発明を完成させるに至った。即ち、本発明は以下の発明を包含する。 As a result of intensive studies to solve the above problems, the present inventor has found that 1-kestose prevents fructose-induced diseases, particularly accumulation of visceral fat, and has completed the present invention. That is, the present invention includes the following inventions.
［１］１−ケストースを含む、フルクトース誘導性疾患の予防又は改善用組成物。
［２］フルクトース誘導性疾患が、フルクトース摂取により誘導されるメタボリックシンドロームである、［１］に記載の組成物。
［３］フルクトース摂取により誘導されるメタボリックシンドロームが、高血圧、糖尿病、インスリン抵抗性、脂質異常症、高脂血症、動脈硬化、脂肪肝、非アルコール性脂肪性肝疾患又は非アルコール性脂肪肝炎である、［２］に記載の組成物。
［４］フルクトース誘導性疾患が肥満又は内臓脂肪蓄積である、［２］に記載の組成物。
［５］［１］〜［４］のいずれかに記載の組成物を含む、飲食品。
［６］［１］〜［４］のいずれかに記載の組成物を含む、医薬品。
[1] A composition for preventing or ameliorating fructose-induced diseases, which comprises 1-kestose.
[2] The composition according to [1], wherein the fructose-induced disease is a metabolic syndrome induced by fructose ingestion.
[3] Metabolic syndrome induced by ingestion of fructose is associated with hypertension, diabetes, insulin resistance, dyslipidemia, hyperlipidemia, arteriosclerosis, fatty liver, non-alcoholic steatohepatitis or non-alcoholic steatohepatitis. The composition according to [2].
[4] The composition according to [2], wherein the fructose-induced disease is obesity or visceral fat accumulation.
[5] A food or drink containing the composition according to any one of [1] to [4].
[6] A pharmaceutical product containing the composition according to any one of [1] to [4].
本発明によると、フルクトース誘導性疾患の予防又は改善するための組成物、特に内臓脂肪の蓄積を予防する組成物や、斯かる組成物を用いた飲食品又は医薬品が得られる。 According to the present invention, a composition for preventing or ameliorating fructose-induced diseases, particularly a composition for preventing the accumulation of visceral fat, and foods and drinks or pharmaceuticals using such a composition can be obtained.
フルクトース誘導性疾患の予防又は改善用組成物（以下「本発明の組成物」とも称す）は、フルクトース誘導性疾患を予防又は改善するために使用され、１−ケストースを含むことを特徴とする。 A composition for preventing or ameliorating fructose-induced diseases (hereinafter, also referred to as "composition of the present invention") is used for preventing or ameliorating fructose-induced diseases, and is characterized by containing 1-kestose.
ケストースは、スクロースにフルクトースが結合して生成される３糖のうち、フルクトースが結合する位置により、１−ケストース、６−ケストース及びネオケストースに分かれるが、「１−ケストース」は、フルクトースがスクロース中のフルクトース単位にβ（２→１）結合している３糖である。このような１−ケストースは、スクロースを基質として、特開昭５８−２０１９８０号公報に開示されているような酵素による酵素反応を行うことにより得ることができる。具体的には、まず、β−フルクトフラノシダーゼをスクロース溶液に添加し、３７℃〜５０℃で２０時間程度静置することにより酵素反応を行って、１−ケストース含有反応液を得る。この１−ケストース含有反応液を、特開２０００−２３２８７８号公報で開示されているようなクロマト分離法に供することよって、１−ケストースと他の糖（ブドウ糖、果糖、ショ糖、４糖以上のオリゴ糖）とを分離して精製し、１−ケストース溶液を得ることができる。続いて、この１−ケストース溶液を濃縮した後、特公平６−７００７５号公報に開示されているような結晶化法で結晶化することにより、１−ケストースを結晶として得ることができる。また、１−ケストースは市販のフラクトオリゴ糖に含まれているため、これをそのまま、あるいは、フラクトオリゴ糖から上述の方法により１−ケストースを分離精製して用いてもよい。その他、市販のベビーオリゴ（登録商標）（物産フードサイエンス株式会社）を用いてもよい。 Kestose is divided into 1-kestose, 6-kestose and neo-kestose depending on the position where fructose binds among the three sugars produced by binding fructose to sucrose. In "1-kestose", fructose is contained in sucrose. It is a trisaccharide that is β (2 → 1) bound to the fructose unit of. Such 1-kestose can be obtained by performing an enzymatic reaction with an enzyme as disclosed in JP-A-58-201980 using sucrose as a substrate. Specifically, first, β-fructofuranosidase is added to a sucrose solution, and the mixture is allowed to stand at 37 ° C. to 50 ° C. for about 20 hours to carry out an enzymatic reaction to obtain a 1-kestose-containing reaction solution. By subjecting this 1-kestose-containing reaction solution to a chromatographic separation method as disclosed in Japanese Patent Application Laid-Open No. 2000-232878, 1-kestose and other sugars (glucose, fructose, sucrose, tetrasaccharide or more) can be used. (Oligosaccharide) can be separated and purified to obtain a 1-kestose solution. Subsequently, after concentrating this 1-kestose solution, 1-kestose can be obtained as crystals by crystallization by a crystallization method as disclosed in Japanese Patent Publication No. 6-70075. Further, since 1-kestose is contained in a commercially available fructooligosaccharide, 1-kestose may be used as it is, or 1-kestose may be separated and purified from the fructooligosaccharide by the above-mentioned method. In addition, a commercially available baby oligo (registered trademark) (Bussan Food Science Co., Ltd.) may be used.
本発明における「フルクトース誘導性疾患」とは、フルクトース（果糖）の摂取によって引き起こされる様々な代謝異常の疾患・症状を意味し、特に、メタボリックシンドロームに関連する疾患・症状、例えばインスリン抵抗性、脂質異常症、脂肪肝、非アルコール性脂肪性肝疾患（ＮＡＦＬＤ）、非アルコール性脂肪肝炎（ＮＡＳＨ）、高脂血症、高尿酸血漿等、及びこれらに起因又は関連して発症する種々の疾患・症状、例えば、糖尿病、高血圧、動脈硬化症等が挙げられる。さらに、フルクトース誘導性疾患には、肥満や内臓脂肪蓄積も含まれる。本発明の組成物は特に、肥満の予防や内臓脂肪蓄積の抑制に効果を奏する。 The "fructose-induced disease" in the present invention means various diseases / symptoms of metabolic disorders caused by ingestion of fructose (frugal sugar), and in particular, diseases / symptoms related to metabolic syndrome, such as insulin resistance and lipids. Abnormalities, fatty liver, non-alcoholic steatohepatitis (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipidemia, hyperuric acid plasma, etc., and various diseases caused by or related to these. Symptoms include, for example, diabetes, hypertension, arteriosclerosis and the like. In addition, fructose-induced diseases also include obesity and visceral fat accumulation. The composition of the present invention is particularly effective in preventing obesity and suppressing visceral fat accumulation.
本発明の組成物は、ヒト又は動物用の医薬品又は飲食品として利用することもできる。本明細書では、動物用の飲食品を飼料とも称す。 The composition of the present invention can also be used as a pharmaceutical product or food or drink for humans or animals. In this specification, food and drink for animals is also referred to as feed.
本発明における医薬品は、本発明の組成物を含有する腸内短鎖脂肪酸産生促進薬等であり得る。上記医薬品の剤型としては、例えば、錠剤、カプセル剤、顆粒剤、散剤、シロップ剤、ドライシロップ剤、液剤、懸濁剤等の経口剤、及び吸入剤、経皮製剤、坐剤等の経腸製剤、点滴剤、注射剤等の非経口剤が挙げられる。上記液剤、懸濁剤等の液体製剤は、服用直前に水又は他の適当な媒体に溶解又は懸濁する形であってもよく、上記錠剤及び顆粒剤は周知の方法でその表面をコーティングされていてもよい。また上記注射剤は、必要に応じて溶解補助剤を含む滅菌蒸留水又は滅菌生理食塩水の溶液であり得る。 The pharmaceutical product in the present invention may be an intestinal short-chain fatty acid production promoter or the like containing the composition of the present invention. Examples of the dosage form of the above-mentioned pharmaceuticals include oral preparations such as tablets, capsules, granules, powders, syrups, dry syrups, liquids and suspensions, and enteral preparations such as inhalants, transdermal preparations and suppositories. Parenteral preparations such as pharmaceuticals, infusions, and injections can be mentioned. The liquid preparations such as the above liquids and suspensions may be dissolved or suspended in water or other suitable medium immediately before administration, and the above tablets and granules are coated on the surface by a well-known method. May be. The injection may be a solution of sterilized distilled water or sterilized physiological saline containing a solubilizing agent, if necessary.
本発明における医薬品は、本発明の組成物に加えて、必要に応じて薬学的に許容される種々の担体、例えば賦形剤、安定化剤、その他の添加剤等を含有していてもよく、あるいは、さらに他の薬効成分、例えば各種ビタミン類、ミネラル類、生薬等を含有していてもよい。当該医薬品は、本発明の組成物に、上述の担体及び他の薬効成分を配合し、常法に従って製造することができる。 In addition to the composition of the present invention, the pharmaceutical product of the present invention may contain various pharmaceutically acceptable carriers such as excipients, stabilizers, other additives and the like, if necessary. Alternatively, it may contain other medicinal ingredients such as various vitamins, minerals, and crude drugs. The pharmaceutical product can be produced according to a conventional method by blending the above-mentioned carrier and other medicinal ingredients with the composition of the present invention.
本発明における飲食品又は飼料は、本発明の組成物を含み、場合によって、腸内短鎖脂肪酸産生促進の効果を企図して、その旨を表示した健康食品、機能性飲食品、特定保健用飲食品、病者用飲食品、家畜、競走馬又は鑑賞動物等のための飼料、ペットフード等としてもあり得る。 The food or drink or feed in the present invention contains the composition of the present invention, and in some cases, a health food, a functional food or drink, for specified health use, which is intended to have an effect of promoting the production of short-chain fatty acids in the intestine and is labeled to that effect. It can also be used as food and drink, food and drink for the sick, feed for livestock, racehorses or ornamental animals, pet food and the like.
本発明における飲食品及び飼料の形態は特に制限されず、本発明の組成物を配合できる全ての形態が含まれる。例えば当該形態としては、固形、半固形又は液状であり得、あるいは、錠剤、チュアブル錠、粉剤、カプセル、顆粒、ドリンク、ゲル、シロップ、経管経腸栄養用流動食等の各種形態が挙げられる。 The forms of food and drink and feed in the present invention are not particularly limited, and include all forms in which the composition of the present invention can be blended. For example, the form may be solid, semi-solid or liquid, or may include various forms such as tablets, chewable tablets, powders, capsules, granules, drinks, gels, syrups, and liquid foods for enteral nutrition. ..
具体的な飲食品の例としては、緑茶、ウーロン茶や紅茶等の茶飲料、コーヒー飲料、清涼飲料、ゼリー飲料、スポーツ飲料、乳飲料、炭酸飲料、果汁飲料、乳酸菌飲料、発酵乳飲料、粉末飲料、ココア飲料、アルコール飲料、精製水等の飲料、バター、ジャム、ふりかけ、マーガリン等のスプレッド類、マヨネーズ、ショートニング、クリーム、ドレッシング類、パン類、米飯類、麺類、パスタ、味噌汁、豆腐、牛乳、ヨーグルト、スープ又はソース類、ベーカリー類（パン、パイ、ケーキ、クッキー、ビスケット、クラッカー等）、菓子（ビスケットやクッキー類、チョコレート、キャンディ、ケーキ、アイスクリーム、チューインガム、タブレット等）、栄養補助食品（丸剤、錠剤、ゼリー剤又はカプセル剤等の形態を有するサプリメント、グラノーラ様シリアル、グラノーラ様スネークバー、シリアルバー）等が挙げられる。 Specific examples of foods and drinks include green tea, tea beverages such as oolong tea and tea, coffee beverages, soft beverages, jelly beverages, sports beverages, dairy beverages, carbonated beverages, fruit juice beverages, lactic acid bacteria beverages, fermented dairy beverages, and powdered beverages. , Cocoa beverages, alcoholic beverages, purified water and other beverages, butter, jam, sprinkles, margarine and other spreads, mayonnaise, shortening, cream, dressings, breads, rice, noodles, pasta, miso soup, tofu, milk, Yogurt, soups or sauces, bakeries (bread, pie, cakes, cookies, biscuits, crackers, etc.), confectionery (biscuits, cookies, chocolates, candy, cakes, ice cream, chewing gum, tablets, etc.), nutritional supplements (breads, pies, cakes, ice cream, chewing gum, tablets, etc.) Supplements in the form of rounds, tablets, jellies or capsules, granola-like serials, granola-like snake bars, serial bars) and the like.
本発明における飼料は、上記飲食品とほぼ同様の組成や形態で利用できることから、本明細書における飲食品に関する記載は、飼料についても同様に当てはめることができる。 Since the feed in the present invention can be used in substantially the same composition and form as the above-mentioned food and drink, the description regarding the food and drink in the present specification can be applied to the feed as well.
本発明における飲食品及び飼料は、本発明の組成物に、飲食品や飼料の製造に用いられる他の飲食品素材、各種栄養素、各種ビタミン、ミネラル、アミノ酸、各種油脂、種々の添加剤（呈味成分、甘味料、有機酸等の酸味料、界面活性剤、ｐＨ調整剤、安定剤、酸化防止剤、色素、フレーバー等）等を配合して、常法に従って製造することができる。あるいは、通常食されている飲食品又は飼料に、本発明の組成物を配合することにより、本発明に係る飲食品又は飼料を製造することもできる。 The food and drink and feed in the present invention are the composition of the present invention, other food and drink materials used in the production of food and drink and feed, various nutrients, various vitamins, minerals, amino acids, various fats and oils, and various additives (presentations). It can be produced according to a conventional method by blending a taste component, a sweetener, an acidulant such as an organic acid, a surfactant, a pH adjuster, a stabilizer, an antioxidant, a pigment, a flavor, etc.). Alternatively, the food or drink or feed according to the present invention can be produced by blending the composition of the present invention with the food or food or feed that is normally eaten.
本発明における医薬品、飲食品又は飼料に含まれる本発明の組成物の含有量は、所望するフルクトース誘導性疾患の予防又は改善に効果が得られる量であればよく、医薬の剤型や飲食品の形態、投与又は摂取する個体の種、症状、年齢、性別等に応じて適宜変更され得るが、１−ケストースの摂取量（投与量）として、例えば、１日あたり４０ｍｇ／ｋｇ体重以上を挙げることができる。係る摂取量は、１日１回に限らず、複数回に分割して摂取してもよい。 The content of the composition of the present invention contained in the drug, food or drink or feed in the present invention may be any amount as long as it is effective in preventing or ameliorating the desired fructose-induced disease, and the dosage form and food and drink of the medicine. The intake (dose) of 1-kestose may be appropriately changed depending on the form, species, symptoms, age, sex, etc. of the individual to be administered or ingested, and for example, 40 mg / kg body weight or more per day is mentioned. be able to. The amount of such intake is not limited to once a day, and may be divided into a plurality of times.
以下に実施例及び比較例を挙げて本発明を具体的に説明するが、これにより本発明の範囲が限定されるものではない。本実施例においては、１−ケストースは「ケストース」と称す。 Hereinafter, the present invention will be specifically described with reference to Examples and Comparative Examples, but the scope of the present invention is not limited thereto. In this embodiment, 1-kestose is referred to as "kestose".
［飼料の調製］
フルクトース誘導性の病態惹起群（ＦＣとも称す）及びケストース群（ＦＫとも称す）の飼料は、高フルクトース飼料（Ｆ２ＨＦｒＤ）（オリエンタル酵母工業株式会社）をベースに、表１の飼料組成にて調製した。具体的には、ＦＣ用としてセルロース５．４９９％及びα化コーンスターチ３．７５０％を、ＦＫ用としてセルロース１．７４９％及びケストース７．５００％を、それぞれ配合した。これらの配合飼料は、グラムあたりのエネルギーがほぼ等しくなるように調製した。正常動物群（ＣＴとも称す）には、通常の飼育に用いる飼料（ＣＲＦ−１）を使用した。ケストースはベビーオリゴ（登録商標）（物産フードサイエンス株式会社）を用いた。
[Preparation of feed]
The feeds of the fructose-induced pathological condition-inducing group (also referred to as FC) and the kestose group (also referred to as FK) were prepared based on the high fructose feed (F2HFrD) (Oriental Yeast Co., Ltd.) with the feed composition shown in Table 1. .. Specifically, 5.499% of cellulose and 3.750% of pregelatinized cornstarch for FC were blended, and 1.749% of cellulose and 7.500% of kestose were blended for FK, respectively. These formula feeds were prepared so that the energies per gram were approximately equal. For the normal animal group (also referred to as CT), the feed (CRF-1) used for normal breeding was used. Baby oligo (registered trademark) (Bussan Food Science Co., Ltd.) was used as kestose.
［動物試験の実施］
入荷後５日間の検疫期間、その後２日間の馴化期間が完了した７週齢のＳＤオスラットを、群分け前日の各群の平均体重及び群分け前日のトリグリセライド（ＴＧとも称す）値が各群ほぼ等しくなるように８匹毎に群分けした後、各飼料を２８日間給餌した。体重測定は、１週間に１回実施した。また、１週間に１回、給餌器ごとに給餌量を測定し、その翌日に給餌器ごとに残量を測定した。給餌量と残量の差から１日あたりの摂餌量を算出した。投与２８日目に動物を安楽死させ、精巣周囲脂肪、腎周囲脂肪、腸間膜脂肪を摘出し、重量を測定した。
[Implementation of animal tests]
The average body weight of each group on the day before grouping and the triglyceride (also called TG) value on the day before grouping were almost the same for each group of 7-week-old SD male rats that had completed a quarantine period of 5 days after arrival and then a habituation period of 2 days. After grouping into groups of 8 animals so that they were equal, each feed was fed for 28 days. Weight measurement was performed once a week. In addition, the amount of feed was measured for each feeder once a week, and the remaining amount was measured for each feeder the next day. The daily feed amount was calculated from the difference between the feed amount and the remaining amount. On the 28th day of administration, the animals were euthanized, peritesticular fat, perrenal fat, and mesenteric fat were removed and weighed.
［実施例１］
上記の通り試験を行い、各飼料における投与２８日目の体重を測定したところ、図１及び表２の結果が得られた。病態惹起群と比較して、ケストース群では体重に差が見られなかった。
[Example 1]
When the test was carried out as described above and the body weight of each feed was measured on the 28th day of administration, the results shown in FIGS. 1 and 2 were obtained. There was no difference in body weight in the kestose group compared to the pathogenic group.
［実施例２］
上記の通り試験を行い、各飼料における投与２６日目から２７日目の１日あたりの摂餌量を算出したところ、図２及び表２の結果が得られた。病態惹起群と比較して、ケストース群では１日あたりの摂餌量に差が見られなかった。
[Example 2]
When the test was carried out as described above and the daily feed amount of each feed was calculated from the 26th day to the 27th day of administration, the results shown in FIGS. 2 and 2 were obtained. There was no difference in daily food intake in the kestose group compared to the pathogenic group.
［実施例３］
上記の通り試験を行い、各飼料における投与２８日目の精巣周囲脂肪重量を測定し、体重１００ｇあたりの重量として算出したところ、図３及び表２の結果が得られた。正常動物群と比較して、病態惹起群では体重１００ｇあたりの精巣周囲脂肪重量が増加したが、ケストース群ではこの増加が見られなかった。よって、内臓脂肪重量の増加に対する抑制効果がケストース群において確認され、ケストースによりメタボリックシンドロームが改善されることがわかった。
[Example 3]
The test was carried out as described above, and the weight of peritesticular fat on the 28th day of administration of each feed was measured and calculated as the weight per 100 g of body weight. The results shown in FIGS. 3 and 2 were obtained. Compared with the normal animal group, the peritesticular fat weight per 100 g of body weight increased in the pathogenic group, but this increase was not observed in the kestose group. Therefore, the inhibitory effect on the increase in visceral fat weight was confirmed in the kestose group, and it was found that kestose improved the metabolic syndrome.
［実施例４］
上記の通り試験を行い、各飼料における投与２８日目の腎周囲脂肪重量を測定し、体重１００ｇあたりの重量として算出したところ、図４及び表２の結果が得られた。正常動物群と比較して、病態惹起群では体重１００ｇあたりの腎周囲脂肪重量が増加したが、ケストース群ではこの増加が見られなかった。よって、内臓脂肪重量の増加に対する抑制効果がケストース群において確認され、ケストースによりメタボリックシンドロームが改善されることがわかった。
[Example 4]
When the test was carried out as described above, the perrenal fat weight on the 28th day of administration of each feed was measured and calculated as the weight per 100 g of body weight, the results shown in FIGS. 4 and 2 were obtained. Compared with the normal animal group, the perirenal fat weight per 100 g of body weight increased in the pathogenic group, but this increase was not observed in the kestose group. Therefore, the inhibitory effect on the increase in visceral fat weight was confirmed in the kestose group, and it was found that kestose improved the metabolic syndrome.
［実施例５］
上記の通り試験を行い、各飼料における投与２８日目の腸間膜脂肪重量を測定し、体重１００ｇあたりの重量として算出したところ、図５及び表２の結果が得られた。正常動物群及び病態惹起群と比較して、ケストース群では体重１００ｇあたりの腸間膜脂肪重量の減少が見られた。よって、ケストース群における内臓脂肪重量の減少効果が確認され、ケストースによりメタボリックシンドロームが予防されることがわかった。
[Example 5]
When the test was carried out as described above, the mesenteric fat weight on the 28th day of administration of each feed was measured and calculated as the weight per 100 g of body weight, the results shown in FIGS. 5 and 2 were obtained. A decrease in mesenteric fat weight per 100 g of body weight was observed in the Kestose group as compared with the normal animal group and the pathogenic group. Therefore, the effect of reducing the weight of visceral fat in the kestose group was confirmed, and it was found that the kestose prevented metabolic syndrome.
［実施例６］
上記の通り試験を行い、各飼料における投与２８日目の精巣周囲脂肪重量、腎周囲脂肪重量、腸間膜脂肪重量を合算し、体重１００ｇあたりの重量として内臓脂肪重量を算出したところ、図６及び表２の結果が得られた。正常動物群と比較して、病態惹起群では体重１００ｇあたりの内臓脂肪重量が増加したが、ケストース群ではこの増加が見られなかった。よって、内臓脂肪重量の増加に対する抑制効果がケストース群において確認され、ケストースによりメタボリックシンドロームが改善されることがわかった。
[Example 6]
The test was carried out as described above, and the weight of visceral fat was calculated as the weight per 100 g of body weight by adding up the weight of peri-anticipatory fat, the weight of perirenal fat, and the weight of mesenteric fat on the 28th day of administration of each feed. And the results shown in Table 2 were obtained. Compared with the normal animal group, the visceral fat weight per 100 g of body weight increased in the pathogenic group, but this increase was not observed in the kestose group. Therefore, the inhibitory effect on the increase in visceral fat weight was confirmed in the kestose group, and it was found that kestose improved the metabolic syndrome.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020046608A JP7025465B2 (en) | 2020-03-17 | 2020-03-17 | Composition for prevention or improvement of fructose-induced diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020046608A JP7025465B2 (en) | 2020-03-17 | 2020-03-17 | Composition for prevention or improvement of fructose-induced diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021145581A true JP2021145581A (en) | 2021-09-27 |
| JP7025465B2 JP7025465B2 (en) | 2022-02-24 |
Family
ID=77847695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020046608A Active JP7025465B2 (en) | 2020-03-17 | 2020-03-17 | Composition for prevention or improvement of fructose-induced diseases |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7025465B2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012031135A (en) * | 2010-06-29 | 2012-02-16 | Kao Corp | Prevention or improving agent for fructose-induced disease |
| WO2018179441A1 (en) * | 2017-03-31 | 2018-10-04 | 物産フードサイエンス株式会社 | Agent for preventing worsening of insulin resistance or ameliorating insulin resistance |
-
2020
- 2020-03-17 JP JP2020046608A patent/JP7025465B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012031135A (en) * | 2010-06-29 | 2012-02-16 | Kao Corp | Prevention or improving agent for fructose-induced disease |
| WO2018179441A1 (en) * | 2017-03-31 | 2018-10-04 | 物産フードサイエンス株式会社 | Agent for preventing worsening of insulin resistance or ameliorating insulin resistance |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7025465B2 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5639759B2 (en) | Novel sweetener with sugar-like taste, production method and use thereof | |
| JP6475610B2 (en) | Anti-lifestyle disease agent and oral composition comprising the same | |
| JP6013712B2 (en) | Biometabolic parameter improving agent comprising D-psicose as an active ingredient | |
| JP5876205B2 (en) | Method for improving deficiency of sweetness of D-sorbose in sweetener comprising D-sorbose and improving sweetness persistence | |
| JP6785509B2 (en) | A composition for preventing or treating metabolic disorders containing exopolysaccharide produced by Leuconostoc mesenteroides as an active ingredient. | |
| JP2024015186A (en) | Composition | |
| JP7265591B2 (en) | Composition for improving brain function | |
| WO2007010975A1 (en) | Use of psicose in agent for prevention of the increase in blood d-fructose level | |
| JP6453897B2 (en) | Slowly digestive sustained energy supplement | |
| CN112399799A (en) | Composition for inhibiting lipopexia | |
| JP7025465B2 (en) | Composition for prevention or improvement of fructose-induced diseases | |
| JPWO2019107531A1 (en) | Composition for suppressing or reducing the increase of blood lipids | |
| JP4022350B2 (en) | Composition having an inhibitory effect on cholesterol elevation and an inhibitory effect on HDL-cholesterol lowering | |
| JP6391959B2 (en) | Non-alcoholic steatohepatitis ameliorating agent and ameliorating nutrition composition | |
| JP2021023188A (en) | Composition for promoting proliferation of genus bifidobacterium bacterium that does not assimilate lactulose | |
| JP2021010348A (en) | Composition for promoting intestinal short-chain fatty acid production | |
| JP2009254242A (en) | Novel sweetener having sugar-like taste, method for producing the same, and use of the sweetener | |
| JP2020130093A (en) | Composition for promoting intestinal butyric acid production | |
| KR101697260B1 (en) | Composition Comprising Voglibose As a Prebiotic for Improving Intestinal Microflora or Preventing Obesity | |
| JP7418992B2 (en) | Composition for promoting the growth of specific Bifidobacterium bacteria in the human intestinal tract | |
| KR101890853B1 (en) | A composition for prevention or treatment of obesity comprising protamine and chitooligosaccharide | |
| JP7369568B2 (en) | Composition for promoting alcohol metabolism | |
| JP7138378B2 (en) | Palatinose syrup that suppresses crystal precipitation and has the ability to suppress blood sugar elevation | |
| JP2020068718A (en) | Composition for reducing blood cholesterol | |
| JP2023055389A (en) | Proliferation promoting agents for bacteria belonging to the genus bacteroides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200609 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210720 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210909 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211224 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220125 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220210 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7025465 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |